Association between growth differentiation factor-15 and cardiovascular risk in patients with type 2 diabetes mellitus

• Main Authors: Fatma E.-Z.M Abu-Bakr, Mona M Abdel-Meguid, Eglal M Qenawy
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2020-01-01
• Series: Al-Azhar Assiut Medical Journal
• Subjects: keywords; cardiovascular disease; growth differentiation factor-15; type 2 diabetes mellitus
• Online Access: http://www.azmj.eg.net/article.asp?issn=1687-1693;year=2020;volume=18;issue=4;spage=380;epage=384;aulast=Abu-Bakr

Background and aim As most diabetic patients have high risk of cardiovascular hazards, the aim was to assess an indicator biomarker that can help us to estimate these hazards in patients with type 2 diabetes (T2D). Patients and methods A total of 80 participants were examined for T2D and divided into two groups: T2D group and control group. To estimate the 10-year risk of atherosclerotic cardiovascular disease, we utilized the Framingham risk score (FRS), the New Pooled Cohort Equation score, Tch/high-density lipoprotein (HDL) ratio, HDL/low-density lipoprotein (LDL) ratio, and serum growth differentiation factor-15 (GDF15). Results The T2D group had higher levels of systolic blood pressure and diastolic blood pressure and lower levels of weight and BMI than control. The T2D group had higher levels of random blood glucose (RBG), glycosylated hemoglobin, and urea. Both the total cholesterol/HDL and LDL/HDL were high significantly in the T2D, whereas FRS was high in the T2D group than control group. The level of serum GDF15 was higher in the T2D group (P=0.000). We found a positive correlation between level of serum GDF15 and BMI (r=0.336, P=0.017), systolic blood pressure (r=0.622, P=0.000), diastolic blood pressure (r=0.572, P=0.000), RBG (r=0.298, P=0.035), and FRS (r=0.415, P=0.003). Conclusion GDF15 can be used as an indicator for measuring cardiovascular hazards in patients with T2D.